Clinical Trials
-
Principal Investigator:
Nobuko Hijiya, MDThe purpose of this study is to learn more about the treatment of children and teenagers whose leukemia has come back (has relapsed) or has not gone away after other treatments (is refractory). Participants will receive the study drug, called carfilzomib in combination with standard chemotherapy, that are dexamethasone, daunorubicin, vincristine and PEG-asparaginase. The study consist of 3 periods: screening, treatment and end of study period. Participants with stable disease or better response at the end of the Induction Cycle will be offered an optional cycle of Consolidation chemotherapy. -
Principal Investigator:
Nobuko Hijiya, MDThe purpose of this study is to determine if a study drug called pembrolizumab is safe and effective in the treatment of children and adolescents who have advanced melanoma, or advanced, relapsed, or refractory PD-L1 positive malignant solid tumor or other lymphoma, relapsed or refractory classical Hodgkin lymphoma (rrcHL), advanced, relapsed or refractory microsatellite-instability-high (MSI-H) solid tumor. Participants might be at least 6 months ( 3 years rrcHL) to less than 18 years old and able to provide the sample for testing the PD-L1 (programmed cell death ligand 1) purpose from an... -
Principal Investigator:
Meyer Kattan, MDWe are interested in learning more about these diseases and how to treat them. Our research program is conducting several studies including: a study to learn if treatment with a drug named dupilumab can help reduce asthma attacks in children, a study to observe a specific type of irritation in the lungs and how it relates to asthma symptoms, and more! If you live in the city or surrounding counties and have an interest in participating in research studies, you may be eligible to join a registry of participants. Our research focuses on children, but all ages are eligible to join. Contribute to... -
Principal Investigator:
Meyer Kattan, MDWe are interested in learning more about these diseases and how to treat them. Our research program is conducting several studies including: a study to learn if treatment with a drug named dupilumab can help reduce asthma attacks in children, a study to observe a specific type of irritation in the lungs and how it relates to asthma symptoms, and more! If you live in the city or surrounding counties and have an interest in participating in research studies, you may be eligible to join a registry of participants. Our research focuses on children, but all ages are eligible to join. Contribute to... -
Principal Investigator:
Ilene Fennoy, MDWe know that puberty is a major time of change! Adolescents develop new decision-making skills and independence. It is possible that some of these changes are due to the hormonal changes during puberty. One of the ways we treat transgender and gender non-conforming teens is to suppress or "block" puberty. We know that this is a safe thing to do for teens because we use it in people who start puberty too early (precocious puberty) and in people who are born very small in order to prolong their growth potential. We are doing this study to continue to understand the impact of this therapy on... -
Principal Investigator:
Dani Dumitriu, MD, PhDThis study aims to understand the impact of the COVID-19 pandemic on mother and infant health outcomes in pregnant women delivering at NewYork-Presbyterian Morgan Stanley Children's Hospital or Allen Pavilion Hospital. Data will be collected through online surveys, video visits, and electronic health records. Additionally, surveys will be distributed to physicians and other healthcare workers involved in newborn care to ask them about their clinical practices during the pandemic. -
Principal Investigator:
Dani Dumitriu, MD, PhDThis study aims to understand the impact of the COVID-19 pandemic on mother and infant health outcomes in pregnant women delivering at NewYork-Presbyterian Morgan Stanley Children's Hospital or Allen Pavilion Hospital. Data will be collected through online surveys, video visits, and electronic health records. Additionally, surveys will be distributed to physicians and other healthcare workers involved in newborn care to ask them about their clinical practices during the pandemic. -
Principal Investigator:
Stephanie Levasseur, MDAlthough supraventricular tachycardia (SVT), including atrial flutter (AF), are the most common causes of intended in-utero fetal therapy, none of the medication used to date has been evaluated for their effects on the mother and her baby in a randomized controlled clinical trial (RCT). In the absence of such evidence, there is no consensus for the optimal management. The purpose of the FAST Research study is to improve the care of pregnancies affected by AF or SVT. The aim of the FAST Registry is to record the treatment your doctor prescribes, your ongoing care, and the outcome of your... -
Principal Investigator:
Stephanie Levasseur, MDAlthough supraventricular tachycardia (SVT), including atrial flutter (AF), are the most common causes of intended in-utero fetal therapy, none of the medication used to date has been evaluated for their effects on the mother and her baby in a randomized controlled clinical trial (RCT). In the absence of such evidence, there is no consensus for the optimal management. The Fetal Atrial Flutter and supraventricular Tachycardia (FAST) Therapy Trial is a prospective multi-center trial that addresses this knowledge gap to guide future fetal atrial flutter & SVT therapy to the best of care. -
Principal Investigator:
Vidhu Thaker, MDWe will enroll children with severe early-onset obesity (BMI - 99th percentile) diagnosed prior to 6 years of age. We will ask questions about their health, eating behavior and perform a brief physical examination. We will collect saliva or blood to perform genetic testing. We will also invite family members to participate in the genetic study.